Headquartered in Waltham, MA Fiscal year ends December NASDAQ: RGEN repligen.com
Repligen Corporation is a global bioprocessing company that develops and commercializes innovative technologies and integrated solutions supporting critical steps in the manufacturing and delivery of biologic drugs. The company serves biopharmaceutical developers, manufacturers, and contract development and manufacturing organizations (CDMOs) worldwide, helping improve productivity, simplify complex workflows, and advance biologic therapies. Repligen's technologies support production across a broad range of biologic modalities, from process development through commercial production. With its recent acquisition of BioLife Solutions, the company has expanded its portfolio into cell therapy consumables, adding a recurring-revenue platform with commercial-stage customer exposure and deep workflow integration. The company trades on the NASDAQ under the ticker RGEN. Updated
A $41.2 million intangible impairment charge turned the quarter into a GAAP loss of $(0.68) per share, the number that will hit screens first, even as adjusted operating margin expanded and management raised full-year revenue guidance with BioLife Solutions now folded in. Keep an eye on the stock.
Merck and Moderna just proved their cancer vaccine works, and the ripple effects reach far beyond either company. Five names stand to collect a toll on every single dose manufactured, but not…
Pre-Market Stock Futures: Futures are trading mixed, with the Nasdaq getting hammered after a gangbuster start to the first full trading week of the third quarter. All of the major indices finished…
Wednesday's top analyst upgrades and downgrades included Array Technology, Blink Charging, Carnival, Carrier Global, DocuSign, Fox, Marathon Petroleum, Occidental Petroleum, PagSeguro Digital, Paramount Global, Salesforce, Viking Therapeutics and Williams Companies.
Thursday's top analyst upgrades and downgrades included Amgen, Archer Daniels Midland, Blackstone, Bloom Energy, Carnival, Chevron, Danaher, EQT, KKR, Nike, PACCAR, Plug Power, PulteGroup, QuantumScape and RingCentral.
Tuesday's top analyst upgrades and downgrades included Ally Financial, CarMax, Dominion Energy, Dynatrace, Exelon, GigaCloud Technology, Gilead Sciences, Intuit, KKR, Lowe’s Companies, Morgan Stanley and Tesla.
For health care investors, 2020 looks like a potentially good year after an especially fruitful JPMorgan Healthcare Conference this past week.
Repligen Corporation is a global bioprocessing company that develops and commercializes innovative technologies and integrated solutions supporting critical steps in the manufacturing and delivery of biologic drugs.
24/7 Wall St.'s 12-month price target for RGEN is $227.37, rated Buy. The Wall Street consensus target is $203.45. RGEN price prediction →
